Efficacy and safety of IBI110 (anti-LAG-3 antibody) plus sintilimab (anti-PD-1 antibody) in patients with advanced alveolar soft part sarcoma: Results from a phase II study

被引：0
|
作者：
Liu, Jiayong
Tan, Zhichao
Fan, Zhengfu
Bai, Chujie
Xue, Ruifeng
Li, Shu
Gao, Tian
Zhang, Lu
Wang, Xinyu
机构：
[1] Peking Univ Canc Hosp, Dept Bone & Soft Tissue Tumor, Beijing, Peoples R China
[2] Peking Univ Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11559
引用
收藏
页数：1
相关论文
共 50 条
  • [1] IBI110 (anti-LAG-3 mAb) as a single agent or in combination with sintilimab (anti-PD-1 mAb) in patients with advanced solid tumors: Updated results from the phase Ia/Ib dose-escalation study
    Xu, Nong
    Mao, Chenyu
    Qian, Jiong
    Zheng, Yulong
    Jiang, Haiping
    Gao, Yuan
    Xiao, Cheng
    Xiong, Anwen
    Li, Wei
    He, Yayi
    Ren, Shengxiang
    Wang, Lei
    Yu, Jia
    Zhu, Jun
    Liu, Ying
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.
    Zhou, Cai
    He, Yayi
    Ren, Shengxiang
    Li, Wei
    Zhu, Jun
    Yu, Jia
    Wang, Lei
    Xiong, Anwen
    Xu, Nong
    Mao, Chenyu
    Pan, Beiqing
    Liu, Ying
    Zhou, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) in first-line advanced squamous non-small cell lung cancer (sqNSCLC): Initial results from a phase Ib study.
    Zhou, Caicun
    Xiong, Anwen
    Li, Wei
    Wang, Lei
    Wu, Fengying
    Yu, Jia
    Mao, Chenyu
    Qian, Jiong
    Zheng, Yulong
    Jiang, Haiping
    Gao, Yuan
    Xiao, Cheng
    Wang, Wenxiang
    Zhuang, Wu
    Yang, Jun
    Sun, Jiya
    Wang, Hongli
    Liu, Ying
    Xu, Nong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] A Phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced ccRCC
    Kim, Miso
    ONCOLOGIST, 2024, 29 : S7 - S7
  • [5] Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma
    Bai, Xue
    Li, Mei
    Chen, Yu
    Si, Lu
    Chen, Jing
    Pu, Xingxiang
    Cheng, Ying
    Zou, Zhengyun
    Zhao, Shiwei
    Li, Tao
    Cai, Shengli
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced HNSCC
    Cho, Byoung Chul
    Hamid, Omid
    Zhu, Xinhua
    Keam, Bhumsuk
    Kaczmar, John M.
    Williamson, Stephen K.
    Birnbaum, Ariel E.
    Dowlati, Afshin
    Dy, Grace K.
    Hager, Steven Jeffrey
    Lynce, Filipa
    McDermott, Raymond S.
    Sarker, Debashis
    Weise, Amy M.
    Yap, Timothy A.
    Yilmaz, Emrullah
    Fang, Fang
    Mani, Jayakumar
    Kroog, Glenn Scott
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Efficacy and safety of sintilimab (anti-PD-1 mAb) for advanced cervical cancer: Results from a Phase II trial
    Gao, Qinglei
    Wang, Jing
    Xu, Qin
    Tang, Ying
    Zhang, Jieqing
    Chang, Baoping
    Xia, Bairong
    Duan, Wei
    Wang, Danbo
    Zhu, Lijing
    An, Ruifang
    Zhang, Guonan
    Tang, Yaling
    Huang, Jianli
    Zhang, Xiang
    Qiu, Hui
    Ji, Wenting
    Li, Li
    Zhu, Jianqing
    Ma, Ding
    CANCER RESEARCH, 2023, 83 (08)
  • [8] Efficacy and Safety of Anti-PD-1 Antibody (IBI308) in Treating Advanced Neuroendocrine Neoplams
    Jia, R.
    Li, Y. L.
    Jin, Y. S.
    Chen, Y.
    Zhang, Y.
    Wan, Y.
    Liu, R. R.
    Zhou, H.
    Jiang, Y. B.
    Xu, Q.
    Xu, J. M.
    NEUROENDOCRINOLOGY, 2018, 106 : 230 - 230
  • [9] A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced ccRCC.
    Kim, Miso
    McDermott, Raymond S.
    Williamson, Stephen K.
    Cho, Byoung Chul
    Dowlati, Afshin
    Lakhani, Nehal J.
    Malhotra, Jyoti
    Kaczmar, John M.
    Papadopoulos, Kyriakos P.
    Safran, Howard
    Aljumaily, Raid
    Mani, Jayakumar
    Fang, Fang
    Chen, Shuquan
    Salvati, Mark
    Lowy, Israel
    Fury, Matthew G.
    Lewis, Karl
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 434 - 434
  • [10] CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
    J. Randolph Hecht
    Jean-Marie Michot
    David Bajor
    Amita Patnaik
    Ki Y. Chung
    Judy Wang
    Gerald Falchook
    James M. Cleary
    Richard Kim
    Anuradha Krishnamurthy
    Omkar Marathe
    Hagop Youssoufian
    Catherine Ellis
    Angela Waszak
    Srimoyee Ghosh
    Hailei Zhang
    Kaitlin Yablonski
    Shruti D. Shah
    Ivan Diaz-Padilla
    Susanna Ulahannan
    BJC Reports, 3 (1):
12345